Federal Circuit Decision Raises Concern over Whether Skinny Labels are Sufficient to Avoid Induced Infringement
FDA Approves Rapid-Acting Insulin
FDA Approves First Biosimilars of 2020
Precedential Opinion Panel to Decide “Printed Publication” Requirements at Institution Stage
Petitioner’s Reply May Expand Arguments to Address New Claim Constructions Adopted After Institution
Celltrion’s and Hospira’s Production of Infliximab Biosimilars Does Not Infringe Remicide®-Related Patent
Federal Circuit: No Tribal Sovereign Immunity in IPRs
Another Lesson in Timing for Disclaimers in CBM Reviews
